MX2021014892A - Composiciones y metodos para el tratamiento del dolor en sujetos con artritis reumatoide. - Google Patents
Composiciones y metodos para el tratamiento del dolor en sujetos con artritis reumatoide.Info
- Publication number
- MX2021014892A MX2021014892A MX2021014892A MX2021014892A MX2021014892A MX 2021014892 A MX2021014892 A MX 2021014892A MX 2021014892 A MX2021014892 A MX 2021014892A MX 2021014892 A MX2021014892 A MX 2021014892A MX 2021014892 A MX2021014892 A MX 2021014892A
- Authority
- MX
- Mexico
- Prior art keywords
- rheumatoid arthritis
- compositions
- methods
- treating pain
- subj ects
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
- C07K16/241—Tumor Necrosis Factors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Immunology (AREA)
- Biochemistry (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Dermatology (AREA)
- Epidemiology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
La presente divulgación se refiere al uso de un anticuerpo anti-receptor de IL6 para tratar un dolor inaceptable en sujetos con artritis reumatoide. Los sujetos con dolor inaceptable pueden tener, p. ej., dolor refractario o dolor refractario estricto.
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201962857247P | 2019-06-04 | 2019-06-04 | |
US201962930966P | 2019-11-05 | 2019-11-05 | |
EP20305191 | 2020-02-27 | ||
PCT/US2020/035871 WO2020247461A1 (en) | 2019-06-04 | 2020-06-03 | Compositions and methods for treating pain in subj ects with rheumatoid arthritis |
Publications (1)
Publication Number | Publication Date |
---|---|
MX2021014892A true MX2021014892A (es) | 2022-06-27 |
Family
ID=71842803
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2021014892A MX2021014892A (es) | 2019-06-04 | 2020-06-03 | Composiciones y metodos para el tratamiento del dolor en sujetos con artritis reumatoide. |
Country Status (14)
Country | Link |
---|---|
US (1) | US20200399380A1 (es) |
EP (1) | EP3980459A1 (es) |
JP (1) | JP2022534794A (es) |
KR (1) | KR20230061198A (es) |
CN (1) | CN115667301A (es) |
AU (1) | AU2020288561A1 (es) |
BR (1) | BR112021024445A2 (es) |
CA (1) | CA3142710A1 (es) |
CO (1) | CO2021017737A2 (es) |
IL (1) | IL288573A (es) |
MA (1) | MA56116A (es) |
MX (1) | MX2021014892A (es) |
TW (1) | TW202110892A (es) |
WO (1) | WO2020247461A1 (es) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2024526414A (ja) * | 2022-04-06 | 2024-07-18 | リジェネロン・ファーマシューティカルズ・インコーポレイテッド | Il-6rアンタゴニストを投与することによってリウマチ性多発筋痛症を処置するための組成物および方法 |
Family Cites Families (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5215534A (en) | 1991-12-02 | 1993-06-01 | Lawrence De Harde | Safety syringe system |
US6659982B2 (en) | 2000-05-08 | 2003-12-09 | Sterling Medivations, Inc. | Micro infusion drug delivery device |
US6629949B1 (en) | 2000-05-08 | 2003-10-07 | Sterling Medivations, Inc. | Micro infusion drug delivery device |
EP1912284B1 (en) | 2005-07-29 | 2012-04-11 | Fujitsu Ltd. | Rf tag and rf tag manufacturing method |
CN102585002A (zh) | 2006-06-02 | 2012-07-18 | 瑞泽恩制药公司 | 人il-6受体的高亲和力抗体 |
JO3417B1 (ar) | 2010-01-08 | 2019-10-20 | Regeneron Pharma | الصيغ المستقرة التي تحتوي على الأجسام المضادة لمضاد مستقبل( interleukin-6 (il-6r |
US9427531B2 (en) | 2010-06-28 | 2016-08-30 | Sanofi-Aventis Deutschland Gmbh | Auto-injector |
US9248242B2 (en) | 2012-04-20 | 2016-02-02 | Safety Syringes, Inc. | Anti-needle stick safety device for injection device |
US20140155827A1 (en) | 2012-12-03 | 2014-06-05 | Mylan, Inc. | Medicament information system and method |
ES2894259T3 (es) * | 2014-09-16 | 2022-02-14 | Sanofi Biotechnology | Composiciones para mejorar la calidad de vida relacionada con la salud de pacientes con artritis reumatoide |
-
2020
- 2020-06-03 TW TW109118636A patent/TW202110892A/zh unknown
- 2020-06-03 CA CA3142710A patent/CA3142710A1/en active Pending
- 2020-06-03 BR BR112021024445A patent/BR112021024445A2/pt unknown
- 2020-06-03 KR KR1020217043303A patent/KR20230061198A/ko unknown
- 2020-06-03 US US16/891,984 patent/US20200399380A1/en active Pending
- 2020-06-03 JP JP2021572280A patent/JP2022534794A/ja active Pending
- 2020-06-03 EP EP20747222.6A patent/EP3980459A1/en active Pending
- 2020-06-03 CN CN202080041385.XA patent/CN115667301A/zh active Pending
- 2020-06-03 WO PCT/US2020/035871 patent/WO2020247461A1/en active Application Filing
- 2020-06-03 MA MA056116A patent/MA56116A/fr unknown
- 2020-06-03 MX MX2021014892A patent/MX2021014892A/es unknown
- 2020-06-03 AU AU2020288561A patent/AU2020288561A1/en active Pending
-
2021
- 2021-12-01 IL IL288573A patent/IL288573A/en unknown
- 2021-12-23 CO CONC2021/0017737A patent/CO2021017737A2/es unknown
Also Published As
Publication number | Publication date |
---|---|
BR112021024445A2 (pt) | 2022-02-15 |
CN115667301A (zh) | 2023-01-31 |
TW202110892A (zh) | 2021-03-16 |
CO2021017737A2 (es) | 2022-05-20 |
AU2020288561A1 (en) | 2021-12-23 |
IL288573A (en) | 2022-02-01 |
JP2022534794A (ja) | 2022-08-03 |
MA56116A (fr) | 2022-04-13 |
CA3142710A1 (en) | 2020-12-10 |
EP3980459A1 (en) | 2022-04-13 |
WO2020247461A1 (en) | 2020-12-10 |
US20200399380A1 (en) | 2020-12-24 |
KR20230061198A (ko) | 2023-05-08 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
PH12020551932A1 (en) | Methods of treating cancers and enhancing efficacy of t cell redirecting therapeutics | |
ZA201903327B (en) | Compositions and methods for the induction of cd8+ t¿cells | |
NZ743124A (en) | Antibodies targeting fc receptor-like 5 and methods of use | |
PH12021550152A1 (en) | Anti-cd112r compositions and methods | |
MX2018001532A (es) | Anticuerpos anti-angptl8 y usos de estos. | |
TN2019000289A1 (en) | Treatment of asthma with anti-tslp antibody | |
PH12020551671A1 (en) | Chimeric receptors to dll3 and methods of use thereof | |
MX2021002180A (es) | Composiciones de inhibidores del receptor de quimiocina c-x-c tipo 4 (cxcr4) y metodos de preparacion y uso. | |
MX2020000342A (es) | Anticuerpos agonistas que se unen a cd137 humano y sus usos. | |
SG10201804000TA (en) | Compositions for the treatment of rheumatoid arthritis and methods of using same | |
MX2021005394A (es) | Co-formulaciones de anticuerpos anti-gen de activacion de linfocitos 3 (anti-lag3) y anticuerpos anti-muerte programada-1 (anti-pd-1). | |
MY187975A (en) | Antigen-binding proteins that activate the leptin receptor | |
MY196448A (en) | Anti-Htra1 Antibodies and Methods of use Thereof | |
MX2023014841A (es) | Composiciones para tratar artritis reumatoide. | |
MX2022001008A (es) | Metodos y composiciones para el diagnostico y el tratamiento de trastornos en pacientes con elevados niveles de cxcl9 y otros biomarcadores. | |
CR20220329A (es) | Anticuerpos anti–mertk y metodos de uso de los mismos | |
IL282375A (en) | For the delay and treatment of synucleopathy, tauopathy and other diseases 2,3,5-TRIMETHYL-6-NONYLCYCLOHEXA-2,5-DIENE-1,4-DIONE | |
MX2021012692A (es) | Anticuerpos anti-mertk y sus metodos de uso. | |
WO2017136834A8 (en) | Methods of differentiating stem cell-derived ectodermal lineage precursors | |
MX2018001849A (es) | Metodos y composiciones que usan bifidobacterium longum para modular la reactividad emocional y tratar o prevenir perturbaciones subclinicas del estado de animo. | |
IL280824A (en) | Methods and compositions for the treatment of rheumatoid arthritis patients | |
MX2021014892A (es) | Composiciones y metodos para el tratamiento del dolor en sujetos con artritis reumatoide. | |
MX2023006777A (es) | Composiciones y métodos que comprenden antagonistas de proteína 2 relacionada con frizzled secretada (sfrp2). | |
MX2022015030A (es) | Composiciones y metodos para el tratamiento del dolor no inflamatorio en sujetos con artritis reumatoide. | |
MX2021001877A (es) | Composiciones y métodos para el tratamiento de lesión pulmonar aguda. |